Study challenges benefit of low-dose alteplase

Patients with acute ischaemic stroke considered at high risk of intracerebral bleeding after thrombolysis do not need to be given alteplase at a lower-than-standard dose, a study shows.

Despite a widespread belief, particularly in Japan, that certain patient subgroups do better on a lower than normal dose of alteplase when thrombolysing after acute ischaemic stroke, an international trial shows no benefit from moving away from standard dosing.

It had been thought that in cases of Asian ethnicity, older age and more severe stroke, patients  needed to be treated more